Skip to content

Effect of hypericum perforatum in obesity

Comparison of the effectiveness of hypericum perforatum with placebo in appetite control in obese and overweight individuals

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110809007265N12
Enrollment
60
Registered
2018-06-30
Start date
2018-05-26
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Obesity due to excess calories

Interventions

Intervention 1: Intervention group: diet + exercise + Hypericum perforatum 750 mg QID for 6 weeks (made by School of Iranian and Complementary Medicine, Mashhad). Intervention 2: Control group: diet +

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: BMI 24.9 to 39.9 Women 18 years to premenopausal and men 18 to 60 years old Consent to participate in the study History of at least one monotherapy failure

Exclusion criteria

Exclusion criteria: Hypothyroidism, Cushing's syndrome, cancer, liver or kidney failure Psychiatric disorders associated with eating like anorexia nervosa and hyperorexia Using drugs effective on weight and metabolism in the previous month Using drugs that interfere with Hypericum perforatum such as protease inhibitors, amiodarone, anticoagulants, cyclophosphamide, cyclosporine, monoamine oxidase inhibitors, phenytoin, tacrolimus, tamoxifen and trazodone drug Drug abuser or alcoholism Breast-feeding, pregnancy or planning a pregnancy during the next two months Pacemaker and any metal device inside the body due to the use of Bioelectrical Impedance Analyzer Disability to do recommended physical activity Allergy to hypericum perforatum

Design outcomes

Primary

MeasureTime frame
Appetite. Timepoint: Before intervention, week 3, week 6. Method of measurement: Visual Analogue Scale.;Body weight. Timepoint: Before intervention, week 3, week 6. Method of measurement: Kilogram.;Waist to hip ratio. Timepoint: Before intervention, week 3, week 6. Method of measurement: Centimeter.

Secondary

MeasureTime frame
Insulin. Timepoint: Before intervention, after intervention. Method of measurement: IU.;Fasting Blood Sugar. Timepoint: Before intervention, after intervention. Method of measurement: Mg/dl.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoda Azizi

Mashhad University of Medical Sciences

azizih@mums.ac.ir+98 51 1855 2188

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026